VOWST™ (SER-109)
Prevention of recurrent Clostridioides difficile infection (rCDI)
ApprovedCommercial
Key Facts
Indication
Prevention of recurrent Clostridioides difficile infection (rCDI)
Phase
Approved
Status
Commercial
Company
About Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profile